Last reviewed · How we verify
Rikkunshito
At a glance
| Generic name | Rikkunshito |
|---|---|
| Also known as | TJ-43, Tsumura Rikkunshito |
| Sponsor | Universitaire Ziekenhuizen KU Leuven |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Acupuncture and Chinese Herbal Medicine for Long COVID (NA)
- Primary Care dySpEpsia rikkuNshiTo (PHASE3)
- Chinese Herbal Medicine Formula Combined With Inhaled Corticosteroids for the Treatment of Mild to Persistent Asthma in Children (NA)
- Traditional Chinese Medicine for the Treatment of Perennial Allergic Rhinitis on Gut Microbiota and Immune-modulation (NA)
- The Effect of Rikkunshito on Gastric Accommodation and Nutrient Volume Tolerance in Functional Dyspepsia (PHASE2)
- The Efficacy and Safety Study of Rikkunshito in Patients With Functional Dyspepsia (PHASE4)
- A Study of Xiang-Sha-Liu-Jun-Zi-Tang in Patients With Irritable Bowel Syndrome (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Rikkunshito CI brief — competitive landscape report
- Rikkunshito updates RSS · CI watch RSS
- Universitaire Ziekenhuizen KU Leuven portfolio CI